Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rBC2LC-N lectin
- Development stage
- Preclinical
- Lead developer
- National Institute of Advanced Industrial Science and Technology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
rBC2LC-N is a recombinant lectin derived from *Burkholderia cenocepacia* that specifically recognizes undifferentiated pluripotent stem cells (ES/iPS cells) and certain cancer cells, particularly pancreatic ductal adenocarcinoma (PDAC). It binds with high affinity to specific O-glycan structures, such as H-type 3 and H-type 4 glycans (Fucα1-2Galβ1-3GalNAc/GlcNAc), which are highly expressed on the surface of undifferentiated cells and cancer stem-like cells. Developed through a collaboration involving the University of Tsukuba, the National Institute of Advanced Industrial Science and Technology (AIST), and Eisai, rBC2LC-N is primarily utilized as a diagnostic probe or research reagent for identifying undifferentiated cells and monitoring residual cancer cells after chemotherapy. Its ability to target chemoresistant residual cells suggests potential applications in targeted therapy or as a diagnostic marker for minimal residual disease.
- Other names
- BC2LC-N lectinBC-2LC-N lectinBC 2LC-N lectinrecombinant BC2LC-N
02
Targets
H-type 3 blood group antigenGlobo-HH1 (H type 1 antigen)
Beyond the preview
Go deeper on rBC2LC-N lectin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rBC2LC-N lectin.